A project funded by the National Institutes of Health will soon launch a digital health device for COVID-19 screening and testing.

Vibrant Health, which focuses on improving the right treatment and research through digital tools, received first aid from NIH in September as part of the institute’s efforts to support digital health solutions to combat the epidemic. The National Cancer Institute and the National Biomedical Imaging and Bioengineering Institute have selected about 200 applications for the projects.

Fairfax, Virginia-based Vibrant Health has received a total of $ 4 million and plans to start a business in the fall, said Vibrant CEO Praduman Jane.

The Vibrent COVID-CARE program has several components once developed. Consists of both web and mobile app, users are asked a series of questions related to symbols, location and public information.

The answers are entered into the algorithm that determines the user’s chances of catching COVID-19. If a user is diagnosed with the virus, the patient can perform a home-based Quickvue test from Quidel or Everlywell. According to Jane, test kits in the local geographic area could be delivered “within a few hours” and the results would be available within 10 minutes.

Results are entered into the app, and the information can be used by health departments to identify outbreaks or monitor infections.

“It starts to close the cycle between the filter and the test kit,” says Jane.

He said the program has yielded results after a year of strategic discussions on market demand and the need to identify infectious diseases. It is intended to help reduce unnecessary tests for patients who do not have the virus.

As the software becomes more sophisticated, software-assisted screening, testing, and monitoring have become a viable option, he said.

Instead of distributing the products directly to consumers, the company is in talks with various potential distributors to start the business, he said.

Both NIH and Vibrent focused on using the device for COVID-19, but Jane said it would “improve” to help the country “prepare for the next epidemic.” He said the use of the proprietary algorithm Vibrent was easily programmed to be used for other diseases, including influenza. To control focus areas and infection trends, the app collects data from various zip codes every day, Jane added.

Machine learning algorithms, along with NH, disease control and prevention centers, and other data sets, provide electronic health record information from APC systems and corner networks and insurance claims, including 19-Jan.

He said the information was identified and shared by public and government sources.

The company used CDC and NIH data to develop 45 models based on the prevalence of COVID-19, influenza, and influenza-like disease in the patient region. The company randomly selected 10,000 cases from NIH and CDC samples to reflect the spread of the disease, one of 45 cases of COVID-19, influenza and influenza-like illnesses.

In December, most states in the United States were exposed to COVID-19, .01 percent influenza and 3.5 percent flu-like illnesses, Jane said.

Restrictions on access to social care and access to health care providers could reduce the number of influenza and similar illnesses reported to the CDC, he said.

The NIH also asked Vibrant to show that the product could improve screening and testing access in unrepresented individuals.

Among the issues that Vibrant wants to address in these populations are reliance on the system, convenience, digital distribution and digital imbalances in mobile technologies, health care information and access to care. The platform works with options for virtual health care visits, self-supporting and staff-supported settings for potential users.

To address technology accessibility and familiarity issues, Vibrant was designed to run the program on devices and software – more than 400,000 people have been used so far, 80 percent of them “in backgrounds not represented in biomedical research.” .

One of the groups, which includes hundreds of black participants in Richmond, Virginia, said the company is incorporating feedback from that group to improve the program.

Many languages ​​are also included in the product, with emphasis on direct language and measurement comprehension.

A spokesman for the NHS National Cancer Institute added that the agency will facilitate the information gathered from the funded studies, as well as the accompanying analysis.

This story first appeared in our sister publication 360Dx, which provides in-depth coverage of the glass test and clinical laboratory market.